Today’s healthcare industry is driven by intensive research and innovation across pharmaceuticals, genetics, biotechnology, medical devices, and increasingly by digital health and data analytics. Deeper understanding of pathophysiology, demographic and epidemiologic transitions, and the rise of chronic diseases have expanded both clinical needs and market opportunities.
In Mexico, the health sector has gained strategic weight in the national economy. According to INEGI, the health sector represented around 6.5% of Mexico’s GDP in 2020, up from roughly 5.5–5.7% in previous years, and generates close to 4% of total employment when considering both public and private services. Mexico Business News
Mexico has consolidated itself as a key player in life sciences in Latin America:
Pharmaceuticals: Mexico is the second-largest pharmaceutical market in Latin America. Recent estimates place the value of the pharmaceuticals market at about 19.8 billion USD in 2024, with solid growth expected toward 2033. IMARC Group
Medical devices: Mexico is the leading exporter of medical devices in Latin America and consistently ranks among the top 10 global exporters, serving as a primary supplier to the United States. The industry was valued at around 12 billion USD in 2023, representing a relevant share of manufacturing GDP and foreign investment. Start-Ops Mexico
Digital transformation is also reshaping the way patients, providers, and companies interact. Telemedicine, electronic prescriptions, remote monitoring, and online scheduling have moved from “future trend” to standard practice, especially after the acceleration triggered by the COVID-19 pandemic. Patients increasingly expect omnichannel engagement for laboratory results, medication management, and medical consultations, creating space for new business models and partnerships. globalhealthsciences.ucsf.edu
What ARNI Consulting Group can do for the health and life sciences sector
ARNI Consulting Group can support companies across the healthcare value chain—pharma, biotech, medical devices, digital health and service providers—through:
Market entry and expansion strategy in Mexico:
Sizing opportunities by segment (hospital, retail, institutional, public tenders).
Competitive mapping and benchmarking against local and multinational players.
Go-to-market design: direct presence, distributors, licensing, or hybrid schemes.
Regulatory and compliance navigation:
High-level guidance on routes for sanitary registration (e.g., COFEPRIS) and alignment with Mexican norms for medicines and medical devices (non-legal, business-focused view).
Risk mapping for logistics, labeling, pharmacovigilance interfaces and post-market surveillance.
Partner and distributor selection:
Identification and pre-screening of distributors, hospital groups, pharmacy chains and specialized importers.
Fit analysis based on infrastructure, coverage, compliance track record and financial robustness.
Structured matchmaking processes with clear key performance indicators.
Nearshoring and manufacturing footprint analysis:
Assessment of locations and clusters for pharma and medical device production.
Evaluation of cost structures, talent availability, logistics and incentives within Mexico and North America.
Customer and stakeholder engagement models:
Design of patient, physician, payer and hospital engagement journeys with digital components.
Support in building data-driven dashboards for commercial performance and market access initiatives.
In a context where healthcare is becoming more technology-intensive, regulated, and data-driven, ARNI combines an international perspective with on-the-ground execution in Mexico to help you de-risk decisions, accelerate market access, and capture sustainable growth in the health and life sciences ecosystem. Contact Us
